122 related articles for article (PubMed ID: 19418497)
1. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
Leman ES; Magheli A; Cannon GW; Mangold L; Partin AW; Getzenberg RH
Prostate; 2009 Aug; 69(11):1188-94. PubMed ID: 19418497
[TBL] [Abstract][Full Text] [Related]
2. EPCA-2: a highly specific serum marker for prostate cancer.
Leman ES; Cannon GW; Trock BJ; Sokoll LJ; Chan DW; Mangold L; Partin AW; Getzenberg RH
Urology; 2007 Apr; 69(4):714-20. PubMed ID: 17445657
[TBL] [Abstract][Full Text] [Related]
3. Association of serum EPCA-2 level with prostate cancer in Chinese Han population.
Wang L; Ma L; Wang X; Li B; Guo S; Qiao Q
Int J Clin Exp Pathol; 2015; 8(8):9397-403. PubMed ID: 26464694
[TBL] [Abstract][Full Text] [Related]
4. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Zeng G; Zhong W
Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
[TBL] [Abstract][Full Text] [Related]
5. EPCA2.22: A Silver Lining for Early Diagnosis of Prostate Cancer.
Pourmand G; Safavi M; Ahmadi A; Houdeh E; Noori M; Mashhadi R; Alizadeh F; Salimi E; Heydari F; Mehrsai A; Pourmand N
Urol J; 2016 Oct; 13(5):2845-2848. PubMed ID: 27734427
[TBL] [Abstract][Full Text] [Related]
6. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
[TBL] [Abstract][Full Text] [Related]
7. Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia.
Zhao Z; Zeng G
Endocr Relat Cancer; 2010 Jun; 17(2):505-12. PubMed ID: 20308359
[TBL] [Abstract][Full Text] [Related]
8. Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
PLoS One; 2011 May; 6(5):e19284. PubMed ID: 21559289
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker.
Leitenberger A; Altwein JE
Eur Urol; 1990; 17(1):12-6. PubMed ID: 1690653
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
[TBL] [Abstract][Full Text] [Related]
11. Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer.
Li K; Luan Q; Zheng J; Li R; Li L; Sun Y; Liu D
Anticancer Res; 2023 Jan; 43(1):441-447. PubMed ID: 36585192
[TBL] [Abstract][Full Text] [Related]
12. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project.
Kane RA; Littrup PJ; Babaian R; Drago JR; Lee F; Chesley A; Murphy GP; Mettlin C
Cancer; 1992 Mar; 69(5):1201-7. PubMed ID: 1371234
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening in the Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
16. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.
Sershon PD; Barry MJ; Oesterling JE
Eur Urol; 1994; 25(4):281-7. PubMed ID: 7519989
[TBL] [Abstract][Full Text] [Related]
18. Early identification of individuals with prostate cancer in negative biopsies.
Dhir R; Vietmeier B; Arlotti J; Acquafondata M; Landsittel D; Masterson R; Getzenberg RH
J Urol; 2004 Apr; 171(4):1419-23. PubMed ID: 15017188
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
20. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
Xie C; Kim HJ; Haw JG; Kalbasi A; Gardner BK; Li G; Rao J; Chia D; Liong M; Punzalan RR; Marks LS; Pantuck AJ; de la Taille A; Wang G; Mukouyama H; Zeng G
J Transl Med; 2011 Apr; 9():43. PubMed ID: 21504557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]